Tessa M F Watt1, Alexander A Brescia2, Shannon L Murray2, David A Burn3, Alexander Wisniewski4, Matthew A Romano2, Steven F Bolling2. 1. Department of Cardiac Surgery, University of Michigan, Ann Arbor, Michigan. Electronic address: tmfwatt@med.umich.edu. 2. Department of Cardiac Surgery, University of Michigan, Ann Arbor, Michigan. 3. Department of Mathematics, Quinnipiac University, Hamden, Connecticut. 4. University of Toledo College of Medicine and Life Sciences, Toledo, Ohio.
Abstract
BACKGROUND: Mitral valve repair (MVr) for severe, degenerative mitral regurgitation is the gold standard, because medical management carries poor prognosis. However, despite clear benefit of MVr, many eligible patients are untreated. This study investigated whether MVr restores patients to normal life expectancy, at any age of operation, by comparing long-term survival of patients after MVr with the life expectancy of the general United States population. METHODS: This retrospective study investigated 1011 patients with degenerative mitral regurgitation who underwent isolated MVr between 2003 and 2017. Parametric distribution analysis was applied to long-term post-MVr mortality data, and Weibull probability plots provided the best-fit distribution by Anderson-Darling Goodness-of-Fit testing. Confidence intervals of the estimated distribution were used to compare additional life expectancy after MVr to the general US population across multiple decades of life. Patients after MVr were categorized by age into decade (range, 20-89 years). RESULTS: The life expectancy of patients after MVr matched the life expectancy of the general US population at any age between 40 and 89 years. Lower-bound one-sided 95% confidence intervals for additional life expectancy were not appreciably different from corresponding median additional life expectancy of the general population. There were few deaths in the 20- to 39-year-old group, limiting predictability, but survival also appeared normative. CONCLUSIONS: These findings suggest that degenerative MVr restores anticipated life expectancy to that of the general population, regardless of age. Although our findings underscore the importance of repair for degenerative mitral disease, larger studies with longer term follow-up are needed to reinforce this finding, particularly for younger patients.
BACKGROUND:Mitral valve repair (MVr) for severe, degenerative mitral regurgitation is the gold standard, because medical management carries poor prognosis. However, despite clear benefit of MVr, many eligible patients are untreated. This study investigated whether MVr restores patients to normal life expectancy, at any age of operation, by comparing long-term survival of patients after MVr with the life expectancy of the general United States population. METHODS: This retrospective study investigated 1011 patients with degenerative mitral regurgitation who underwent isolated MVr between 2003 and 2017. Parametric distribution analysis was applied to long-term post-MVr mortality data, and Weibull probability plots provided the best-fit distribution by Anderson-Darling Goodness-of-Fit testing. Confidence intervals of the estimated distribution were used to compare additional life expectancy after MVr to the general US population across multiple decades of life. Patients after MVr were categorized by age into decade (range, 20-89 years). RESULTS: The life expectancy of patients after MVr matched the life expectancy of the general US population at any age between 40 and 89 years. Lower-bound one-sided 95% confidence intervals for additional life expectancy were not appreciably different from corresponding median additional life expectancy of the general population. There were few deaths in the 20- to 39-year-old group, limiting predictability, but survival also appeared normative. CONCLUSIONS: These findings suggest that degenerative MVr restores anticipated life expectancy to that of the general population, regardless of age. Although our findings underscore the importance of repair for degenerative mitral disease, larger studies with longer term follow-up are needed to reinforce this finding, particularly for younger patients.
Authors: Alec Vahanian; Helmut Baumgartner; Jeroen Bax; Eric Butchart; Robert Dion; Gerasimos Filippatos; Frank Flachskampf; Roger Hall; Bernard Iung; Jaroslaw Kasprzak; Patrick Nataf; Pilar Tornos; Lucia Torracca; Arnold Wenink Journal: Eur Heart J Date: 2007-01-26 Impact factor: 29.983
Authors: Rick A Nishimura; Catherine M Otto; Robert O Bonow; Blase A Carabello; John P Erwin; Lee A Fleisher; Hani Jneid; Michael J Mack; Christopher J McLeod; Patrick T O'Gara; Vera H Rigolin; Thoralf M Sundt; Annemarie Thompson Journal: J Am Coll Cardiol Date: 2017-03-15 Impact factor: 24.094
Authors: Rakesh M Suri; Hartzell V Schaff; Joseph A Dearani; Thoralf M Sundt; Richard C Daly; Charles J Mullany; Maurice Enriquez-Sarano; Thomas A Orszulak Journal: Ann Thorac Surg Date: 2006-09 Impact factor: 4.330
Authors: Maurice Enriquez-Sarano; Jean-François Avierinos; David Messika-Zeitoun; Delphine Detaint; Maryann Capps; Vuyisile Nkomo; Christopher Scott; Hartzell V Schaff; A Jamil Tajik Journal: N Engl J Med Date: 2005-03-03 Impact factor: 91.245
Authors: R O Bonow; B Carabello; A C de Leon; L H Edmunds; B J Fedderly; M D Freed; W H Gaasch; C R McKay; R A Nishimura; P T O'Gara; R A O'Rourke; S H Rahimtoola; J L Ritchie; M D Cheitlin; K A Eagle; T J Gardner; A Garson; R J Gibbons; R O Russell; T J Ryan; S C Smith Journal: Circulation Date: 1998-11-03 Impact factor: 29.690
Authors: Karine Toledano; Lawrence G Rudski; Thao Huynh; François Béïque; John Sampalis; Jean-François Morin Journal: Can J Cardiol Date: 2007-03-01 Impact factor: 5.223
Authors: Alexander A Brescia; Michael J Paulsen; Tessa M F Watt; Liza M Rosenbloom; Alexander M Wisniewski; Jun Li; Guihua Wang; Donald S Likosky; Wallace J Hopp; Steven F Bolling Journal: Ann Thorac Surg Date: 2020-07-18 Impact factor: 4.330
Authors: Muhammed Gerçek; Fabian Roder; Tanja K Rudolph; Vera Fortmeier; Armin Zittermann; Volker Rudolph; Kai P Friedrichs Journal: Clin Res Cardiol Date: 2021-04-10 Impact factor: 5.460